{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:24:53Z","timestamp":1779243893348,"version":"3.51.4"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>While chemotherapy treatment options for patients with solid and hematologic malignancies have dramatically improved over recent years, chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) remain major barriers to delivering treatment at full doses and optimal timing. Despite concurrent advances in granulocyte colony-stimulating factor (G-CSF) administration, multiple barriers to the administration of and disparities in the access to these agents remain. The introduction of new, emerging agents, including biosimilars and novel therapies show promise in improving outcomes for CIN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The introduction of biosimilar filgrastim products has improved access to G-CSF administration by driving marketplace competition and has reduced costs for both patients and healthcare systems without sacrificing efficacy. Emerging therapies to address similar issues include long-acting G-CSF products, efbemalenograstim alfa and eflapegrastin-xnst, as well as agents with novel mechanisms of action, plinabulin and trilaciclib. These agents have shown efficacy and cost-saving benefits in certain populations and disease groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Multiple emerging agents show promise in decreasing the burden of CIN. Use of these therapies will reduce access disparities and will improve outcomes for patients with cancer receiving cytotoxic chemotherapy. Many ongoing trials are underway to evaluate the roles of these agents for more widespread use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000952","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:07:31Z","timestamp":1684922851000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps"],"prefix":"10.1097","volume":"35","author":[{"given":"Jeffrey","family":"Crawford","sequence":"first","affiliation":[{"name":"George Barth Geller Professor for Research in Cancer, Department of Medicine, Lead PI of NCTN LAPS Grant, Duke Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Oswalt","sequence":"additional","affiliation":[{"name":"Hematology & Oncology, Department of Medicine, Duke University Health System, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"issue":"(Suppl 5)","key":"R1-20250526","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well established and recently emerging clinical data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001813-200304000-00002","article-title":"Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients","volume":"14","author":"Molineux","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1007\/s00520-022-07226-9","article-title":"A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices","volume":"30","author":"Rifkin","year":"2022","journal-title":"Support Care Cancer"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal management of neutropenic fever in patients with cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J Oncol Pract"},{"key":"R14-20250526","first-page":"366","article-title":"Biosimilars: still not quite ready for prime time","volume":"41","author":"Rumore","year":"2016","journal-title":"P T"},{"key":"R15-20250526","first-page":"532","article-title":"Pharmacist substitution of biological products: issues and considerations","volume":"21","author":"Li","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2146\/ajhp130119","article-title":"Biosimilars: implications for health-system pharmacists","volume":"70","author":"Lucio","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of healthcare systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R18-20250526","first-page":"541","article-title":"Pegfilgrastim biosimilars: where are we now?","volume":"12","author":"Selby","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"R19-20250526","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1200\/OP.20.00994","article-title":"Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the oncology care model framework","volume":"17","author":"Wang","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"e2133474","DOI":"10.1001\/jamanetworkopen.2021.33474","article-title":"Trends in use of granulocyte colony-stimulating factor following introduction of biosimilars among adults with cancer and commercial or medicare insurance from 2014 to 2019","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"e2100276","DOI":"10.1200\/GO.21.00276","article-title":"Biosimilar versus originator pegfilgrastim for preventing chemotherapy-induced neutropenia: a phase III randomized, multicenter, evaluator-blinded, noninferiority study","volume":"8","author":"Kowalyszyn","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40487-022-00207-2","article-title":"Pegfilgrastim biosimilars in US supportive oncology: a narrative review of administration options and economic considerations to maximize patient benefit","volume":"10","author":"Humphreys","year":"2022","journal-title":"Oncol Ther"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.V116.21.1485.1485","article-title":"F-627, a G-CSF dimer, stimulated a more rapid neutrophil recovery in cyclophosphamide-treated monkeys compared to monomer Rhg-CSFs","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2020.09.199","article-title":"Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing","volume":"92","author":"Barrett","year":"2020","journal-title":"Exp Hematol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1634\/theoncologist.2020-0105","article-title":"Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial","volume":"25","author":"Schwartzberg","year":"2020","journal-title":"Oncologist"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1002\/cam4.3227","article-title":"A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): a phase 3 study","volume":"9","author":"Cobb","year":"2020","journal-title":"Cancer Med"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-019-03998-w","article-title":"Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies","volume":"85","author":"Tonra","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"644608","DOI":"10.3389\/fonc.2021.644608","article-title":"Plinabulin, a distinct microtubule-targeting chemotherapy, promotes M1-like macrophage polarization and antitumor immunity","volume":"11","author":"Natoli","year":"2021","journal-title":"Front Oncol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.cad.0000182745.01612.8a","article-title":"NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent","volume":"17","author":"Nicholson","year":"2006","journal-title":"Anticancer Drugs"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1182\/blood-2010-12-323857","article-title":"A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells","volume":"117","author":"Singh","year":"2011","journal-title":"Blood"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"e2145446","DOI":"10.1001\/jamanetworkopen.2021.45446","article-title":"Efficacy of plinabulin vs pegfilgrastim for prevention of docetaxel-induced neutropenia in patients with solid tumors: a randomized clinical trial","volume":"5","author":"Blayney","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"(Suppl)","key":"R38-20250526","doi-asserted-by":"crossref","first-page":"abstr533","DOI":"10.1200\/JCO.2021.39.15_suppl.533","article-title":"Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention [2021 ASCO Annual Meeting Abstract #533]","volume":"15","author":"Blayney","year":"2021","journal-title":"J Clin Oncol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1078155218770904","article-title":"Role of cyclin-dependent kinase 4\/6 inhibitors in the current and future eras of cancer treatment","volume":"25","author":"Parylo","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","article-title":"Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study","volume":"38","author":"Hart","year":"2021","journal-title":"Adv Ther"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial","volume":"148","author":"Daniel","year":"2020","journal-title":"Int J Cancer"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann Oncol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1002\/cam4.4089","article-title":"Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials","volume":"10","author":"Ferrarotto","year":"2021","journal-title":"Cancer Med"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","article-title":"Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies","volume":"22","author":"Weiss","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"(Suppl 1)","key":"R51-20250526","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13696998.2021.2014163","article-title":"Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy","volume":"24","author":"Abraham","year":"2021","journal-title":"J Med Econ"},{"key":"R52-20250526","first-page":"435","article-title":"Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States","volume":"28","author":"Abraham","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"697908","DOI":"10.3389\/fonc.2021.697908","article-title":"Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era","volume":"11","author":"Lyman","year":"2021","journal-title":"Front Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:04:38Z","timestamp":1748300678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000952","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]}}}